What is Lexicon Pharmaceuticals Inc's earnings per share (EPS)?

Lexicon Pharmaceuticals Inc (LXRX) reported diluted earnings per share of $-0.14 for fiscal year 2025. This represents a 77.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexicon Pharmaceuticals Inc Financials

LXRX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Lexicon Pharmaceuticals Inc (LXRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LXRX FY2025 2026-05-07

Lexicon’s economics are still driven by development spending, while near-zero cost of revenue leaves cash burn concentrated in overhead and R&D.

FY2025’s improvement in operating losses was mostly a cost reset, not just better sales, with operating loss narrowing from -$197.1M to -$48.9M versus FY2024. Because R&D still exceeded revenue in FY2025, the company remains economically organized more like a developer than a fully self-funding commercial business.

Free cash flow matched operating cash flow at -$67.9M in FY2025 because capex was $0, so the year’s cash use came from the core operating model rather than from building out physical assets. That makes Lexicon an asset-light cash consumer: better cash generation depends mainly on expense discipline and revenue scaling, not on cutting factory-style investment.

Liquidity looks comfortable on paper, with a current ratio of 4.9x and debt-to-equity of 0.5x, so near-term bills are not the main pressure point. But year-end cash of $34.3M covered only 50.6% of FY2025 operating cash burn, which means the balance sheet is still carrying the business while operations remain cash negative.

Financial Health Signals

Financial Health Score 68/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Lexicon Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-7.43

Lexicon Pharmaceuticals Inc scores -7.43, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.0B) relative to total liabilities ($77.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Lexicon Pharmaceuticals Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.35x

For every $1 of reported earnings, Lexicon Pharmaceuticals Inc generates $1.35 in operating cash flow (-$67.9M OCF vs -$50.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$49.8M

YoY+60.2%

5Y CAGR+15.7%

10Y CAGR-9.1%

Lexicon Pharmaceuticals Inc generated $49.8M in revenue in fiscal year 2025. This represents an increase of 60.2% from the prior year.

EBITDA

-$48.3M

YoY+75.4%

Lexicon Pharmaceuticals Inc's EBITDA was -$48.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 75.4% from the prior year.

Net Income

-$50.3M

YoY+74.9%

Lexicon Pharmaceuticals Inc reported -$50.3M in net income in fiscal year 2025. This represents an increase of 74.9% from the prior year.

EPS (Diluted)

$-0.14

YoY+77.8%

Lexicon Pharmaceuticals Inc earned $-0.14 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$67.9M

YoY+62.3%

Lexicon Pharmaceuticals Inc generated -$67.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 62.3% from the prior year.

Cash & Debt

$34.3M

YoY-48.5%

5Y CAGR-22.9%

10Y CAGR-16.3%

Lexicon Pharmaceuticals Inc held $34.3M in cash against $49.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

366M

YoY+0.8%

Lexicon Pharmaceuticals Inc had 366M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

99.5%

YoY+1.4pp

5Y CAGR+7.5pp

10Y CAGR-0.5pp

Lexicon Pharmaceuticals Inc's gross margin was 99.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.

Operating Margin

-98.2%

YoY+536.0pp

5Y CAGR+101.0pp

10Y CAGR-99.3pp

Lexicon Pharmaceuticals Inc's operating margin was -98.2% in fiscal year 2025, reflecting core business profitability. This is up 536.0 percentage points from the prior year.

Net Margin

-101.1%

YoY+543.7pp

5Y CAGR+143.0pp

10Y CAGR-97.5pp

Lexicon Pharmaceuticals Inc's net profit margin was -101.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 543.7 percentage points from the prior year.

Return on Equity

-46.8%

YoY+90.5pp

5Y CAGR-9.4pp

10Y CAGR-45.2pp

Lexicon Pharmaceuticals Inc's ROE was -46.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 90.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$61.1M

YoY-27.7%

5Y CAGR-16.8%

10Y CAGR-4.3%

Lexicon Pharmaceuticals Inc invested $61.1M in research and development in fiscal year 2025. This represents a decrease of 27.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Lexicon Pharmaceuticals Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

LXRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$49.8M+60.2%	$31.1M+2481.5%	$1.2M+766.2%	$139K-53.4%	$298K-98.8%	$24.0M
Cost of Revenue	$274K-55.5%	$616K+624.7%	$85K	$0	$0-100.0%	$1.9M
Gross Profit	$49.5M+62.6%	$30.5M+2622.5%	$1.1M+705.0%	$139K-53.4%	$298K-98.6%	$22.1M
R&D Expenses	$61.1M-27.7%	$84.5M+43.5%	$58.9M+11.5%	$52.8M-4.1%	$55.0M-64.2%	$153.6M
SG&A Expenses	$37.3M-73.9%	$143.1M+25.5%	$114.0M+137.1%	$48.1M+48.7%	$32.3M-31.5%	$47.2M
Operating Income	-$48.9M+75.2%	-$197.1M-14.8%	-$171.8M-70.5%	-$100.8M-15.7%	-$87.1M-82.2%	-$47.8M
Interest Expense	N/A	N/A	N/A	$2.8M+246.6%	$802K-94.5%	$14.5M
Income Tax	N/A	$0	$0	$0	$0	N/A
Net Income	-$50.3M+74.9%	-$200.4M-13.1%	-$177.1M-73.7%	-$101.9M-16.2%	-$87.8M-49.8%	-$58.6M
EPS (Diluted)	$-0.14+77.8%	$-0.63+21.3%	$-0.80-29.0%	$-0.62-3.3%	$-0.60-13.2%	$-0.53

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$21.1M+284.2%	$5.5M-61.3%	$14.2M-50.9%	$28.9M+2187.3%	$1.3M-95.2%	$26.6M+1417.4%	$1.8M+6.3%	$1.6M
Cost of Revenue	$108K-46.3%	$201K+1910.0%	$10K-69.7%	$33K+10.0%	$30K-91.4%	$348K+390.1%	$71K-57.2%	$166K
Gross Profit	$21.0M+296.7%	$5.3M-62.7%	$14.2M-50.8%	$28.8M+2240.3%	$1.2M-95.3%	$26.2M+1460.8%	$1.7M+13.4%	$1.5M
R&D Expenses	$12.8M+12.7%	$11.3M-39.7%	$18.8M+19.1%	$15.7M+2.9%	$15.3M-42.7%	$26.7M+3.5%	$25.8M+46.1%	$17.6M
SG&A Expenses	$9.2M+5.4%	$8.8M+15.2%	$7.6M-18.7%	$9.3M-19.5%	$11.6M-64.0%	$32.3M-18.5%	$39.6M+1.0%	$39.2M
Operating Income	-$996K+93.3%	-$14.8M-21.3%	-$12.2M-426.2%	$3.7M+114.5%	-$25.7M+21.6%	-$32.7M+48.6%	-$63.7M-15.1%	-$55.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.0M+93.3%	-$15.5M-21.6%	-$12.8M-492.7%	$3.3M+112.9%	-$25.3M+25.1%	-$33.8M+47.9%	-$64.8M-21.3%	-$53.4M
EPS (Diluted)	$0.00	N/A	$-0.04-500.0%	$0.01+114.3%	$-0.07	N/A	$-0.18-5.9%	$-0.17

LXRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$185.0M-38.0%	$298.4M+30.1%	$229.4M+18.1%	$194.3M+41.9%	$136.9M-32.8%	$203.8M
Current Assets	$101.9M-58.6%	$246.2M+39.4%	$176.5M+25.3%	$140.9M+58.4%	$88.9M-43.6%	$157.7M
Cash & Equivalents	$34.3M-48.5%	$66.7M+196.7%	$22.5M-51.5%	$46.3M-27.7%	$64.1M-49.3%	$126.3M
Inventory	$281K+21.6%	$231K-39.4%	$381K	$0	N/A	$0
Accounts Receivable	$2.4M-31.4%	$3.5M+243.9%	$1.0M+3507.1%	$28K+100.0%	$14K-96.5%	$395K
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M
Total Liabilities	$77.4M-49.2%	$152.5M+11.8%	$136.3M+76.6%	$77.2M+231.0%	$23.3M-50.8%	$47.4M
Current Liabilities	$20.9M-53.9%	$45.2M+43.4%	$31.5M+36.1%	$23.2M+4.7%	$22.1M-52.7%	$46.8M
Long-Term Debt	$49.4M-50.7%	$100.3M+0.8%	$99.5M+104.8%	$48.6M	$0	$0
Total Equity	$107.5M-26.3%	$145.9M+56.8%	$93.1M-20.5%	$117.1M+3.1%	$113.6M-27.4%	$156.4M
Retained Earnings	-$2.0B-2.6%	-$2.0B-11.3%	-$1.8B-11.1%	-$1.6B-6.9%	-$1.5B-6.3%	-$1.4B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$268.8M+45.3%	$185.0M-10.2%	$205.9M-8.7%	$225.6M-24.2%	$297.7M-0.3%	$298.4M-7.1%	$321.1M-14.0%	$373.4M
Current Assets	$186.0M+82.6%	$101.9M-16.8%	$122.5M-15.5%	$145.1M-41.0%	$245.8M-0.2%	$246.2M-8.3%	$268.6M-16.3%	$320.8M
Cash & Equivalents	$38.1M+11.0%	$34.3M-30.9%	$49.7M+132.4%	$21.4M-66.0%	$62.9M-5.7%	$66.7M+92.9%	$34.6M-3.0%	$35.6M
Inventory	$276K-1.8%	$281K+77.8%	$158K-6.0%	$168K-16.4%	$201K-13.0%	$231K-63.7%	$636K+8.7%	$585K
Accounts Receivable	$11.8M+394.1%	$2.4M+2.1%	$2.3M+6.9%	$2.2M-95.4%	$47.4M+1266.2%	$3.5M+20.0%	$2.9M+10.5%	$2.6M
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M
Total Liabilities	$66.0M-14.8%	$77.4M-9.7%	$85.8M-10.8%	$96.1M-44.9%	$174.6M+14.5%	$152.5M+6.9%	$142.6M+6.9%	$133.4M
Current Liabilities	$9.9M-52.6%	$20.9M-3.9%	$21.7M-37.7%	$34.8M-68.5%	$110.7M+144.6%	$45.2M+25.5%	$36.0M+29.3%	$27.9M
Long-Term Debt	$49.7M+0.6%	$49.4M-12.6%	$56.5M+0.7%	$56.1M-4.3%	$58.6M-41.5%	$100.3M+0.4%	$99.9M+0.4%	$99.5M
Total Equity	$202.9M+88.6%	$107.5M-10.5%	$120.2M-7.2%	$129.4M+5.2%	$123.0M-15.7%	$145.9M-18.2%	$178.5M-25.6%	$240.0M
Retained Earnings	-$2.0B-0.1%	-$2.0B-0.8%	-$2.0B-0.6%	-$2.0B+0.2%	-$2.0B-1.3%	-$2.0B-1.7%	-$1.9B-3.5%	-$1.9B

LXRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$67.9M+62.0%	-$178.8M-10.4%	-$161.9M-82.2%	-$88.9M-2.1%	-$87.0M+39.1%	-$143.0M
Capital Expenditures	$0-100.0%	$1.0M+119.4%	$470K-64.6%	$1.3M+8.6%	$1.2M+1303.4%	$87K
Free Cash Flow	-$67.9M+62.3%	-$179.8M-10.7%	-$162.4M-80.1%	-$90.2M-2.2%	-$88.2M+38.3%	-$143.1M
Investing Cash Flow	$113.0M+834.9%	-$15.4M+69.2%	-$49.9M+29.7%	-$71.1M-3468.6%	$2.1M-99.4%	$380.8M
Financing Cash Flow	-$48.5M-120.3%	$238.3M+26.8%	$188.0M+32.2%	$142.2M+526.2%	$22.7M+115.4%	-$147.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$1.7M+110.0%	$824K-4.6%	$864K-67.7%	$2.7M+160.7%	$1.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$14.7M+14.5%	-$17.2M+27.7%	-$23.8M-240.3%	$17.0M+138.8%	-$43.8M-103.7%	-$21.5M+59.9%	-$53.6M-10.5%	-$48.5M
Capital Expenditures	N/A	$0	$0	N/A	N/A	$474K+54.4%	$307K+22.8%	$250K
Free Cash Flow	N/A	-$17.2M+27.7%	-$23.8M	N/A	N/A	-$22.0M+59.3%	-$53.9M-10.5%	-$48.8M
Investing Cash Flow	-$70.3M-1554.7%	$4.8M-90.7%	$52.1M+236.7%	$15.5M-61.8%	$40.6M-24.4%	$53.7M+0.4%	$53.5M+533.9%	-$12.3M
Financing Cash Flow	$88.8M+3132.3%	-$2.9M	$0+100.0%	-$45.0M-7767.1%	-$572K-450.0%	-$104K+88.6%	-$916K-6442.9%	-$14K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0	$0	$0

LXRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	99.5%+1.4pp	98.0%+5.1pp	92.9%-7.1pp	100.0%0.0pp	100.0%+8.0pp	92.0%
Operating Margin	-98.2%+536.0pp	-634.2%+13630.7pp	-14264.9%+58224.3pp	-72489.2%-43264.4pp	-29224.8%-29025.6pp	-199.2%
Net Margin	-101.1%+543.7pp	-644.8%+14066.1pp	-14710.9%+58630.1pp	-73341.0%-43892.0pp	-29449.0%-29204.9pp	-244.1%
Return on Equity	-46.8%+90.5pp	-137.3%+52.9pp	-190.2%-103.2pp	-87.0%-9.8pp	-77.3%-39.8pp	-37.5%
Return on Assets	-27.2%+39.9pp	-67.2%+10.1pp	-77.2%-24.7pp	-52.5%+11.6pp	-64.1%-35.4pp	-28.7%
Current Ratio	4.88-0.6	5.44-0.2	5.60-0.5	6.08+2.1	4.02+0.6	3.37
Debt-to-Equity	0.46-0.2	0.69-0.4	1.07+0.7	0.41+0.4	0.000.0	0.00
FCF Margin	-136.2%+442.3pp	-578.5%+12907.1pp	-13485.6%+51389.9pp	-64875.5%-35265.5pp	-29610.1%-29013.9pp	-596.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	99.5%+3.1pp	96.3%-3.6pp	99.9%+0.0pp	99.9%+2.3pp	97.6%-1.1pp	98.7%+2.7pp	95.9%+6.0pp	89.9%
Operating Margin	-4.7%+264.4pp	-269.1%-183.2pp	-85.9%-98.9pp	12.9%+2047.7pp	-2034.8%-1911.5pp	-123.3%+3516.3pp	-3639.6%-278.7pp	-3360.9%
Net Margin	-4.9%+277.8pp	-282.7%-192.7pp	-90.0%-101.3pp	11.3%+2015.6pp	-2004.4%-1877.2pp	-127.2%+3576.3pp	-3703.5%-459.5pp	-3244.0%
Return on Equity	-0.5%+13.9pp	-14.4%-3.8pp	-10.6%-13.1pp	2.5%+23.1pp	-20.6%+2.6pp	-23.1%+13.2pp	-36.3%-14.0pp	-22.3%
Return on Assets	-0.4%+8.0pp	-8.4%-2.2pp	-6.2%-7.6pp	1.4%+9.9pp	-8.5%+2.8pp	-11.3%+8.9pp	-20.2%-5.9pp	-14.3%
Current Ratio	18.79+13.9	4.88-0.8	5.64+1.5	4.16+1.9	2.22-3.2	5.44-2.0	7.45-4.1	11.51
Debt-to-Equity	0.24-0.2	0.46-0.0	0.47+0.0	0.43-0.0	0.48-0.2	0.69+0.1	0.56+0.1	0.41
FCF Margin	N/A	-313.7%-145.7pp	-168.1%	N/A	N/A	-82.7%+2998.8pp	-3081.5%-119.1pp	-2962.4%

Similar Companies

Aura Biosciences, Inc. AURA

$744.7M

Fulcrum Therapeutics FULC

$250.5M

Astria Therapeutics Inc ATXS

$718.1M

Solid Bioscience SLDB

$785.6M

Inhibrx Biosciences Inc INBX

$1.2B

Frequently Asked Questions

What is Lexicon Pharmaceuticals Inc's annual revenue?

Lexicon Pharmaceuticals Inc (LXRX) reported $49.8M in total revenue for fiscal year 2025. This represents a 60.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexicon Pharmaceuticals Inc's revenue growing?

Lexicon Pharmaceuticals Inc (LXRX) revenue grew by 60.2% year-over-year, from $31.1M to $49.8M in fiscal year 2025.

Is Lexicon Pharmaceuticals Inc profitable?

No, Lexicon Pharmaceuticals Inc (LXRX) reported a net income of -$50.3M in fiscal year 2025, with a net profit margin of -101.1%.

What is Lexicon Pharmaceuticals Inc's EBITDA?

Lexicon Pharmaceuticals Inc (LXRX) had EBITDA of -$48.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Lexicon Pharmaceuticals Inc have?

As of fiscal year 2025, Lexicon Pharmaceuticals Inc (LXRX) had $34.3M in cash and equivalents against $49.4M in long-term debt.

What is Lexicon Pharmaceuticals Inc's gross margin?

Lexicon Pharmaceuticals Inc (LXRX) had a gross margin of 99.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexicon Pharmaceuticals Inc's operating margin?

Lexicon Pharmaceuticals Inc (LXRX) had an operating margin of -98.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lexicon Pharmaceuticals Inc's net profit margin?

Lexicon Pharmaceuticals Inc (LXRX) had a net profit margin of -101.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lexicon Pharmaceuticals Inc's return on equity (ROE)?

Lexicon Pharmaceuticals Inc (LXRX) has a return on equity of -46.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexicon Pharmaceuticals Inc's free cash flow?

Lexicon Pharmaceuticals Inc (LXRX) generated -$67.9M in free cash flow during fiscal year 2025. This represents a 62.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexicon Pharmaceuticals Inc's operating cash flow?

Lexicon Pharmaceuticals Inc (LXRX) generated -$67.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lexicon Pharmaceuticals Inc's total assets?

Lexicon Pharmaceuticals Inc (LXRX) had $185.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexicon Pharmaceuticals Inc's capital expenditures?

Lexicon Pharmaceuticals Inc (LXRX) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lexicon Pharmaceuticals Inc spend on research and development?

Lexicon Pharmaceuticals Inc (LXRX) invested $61.1M in research and development during fiscal year 2025.

How many shares does Lexicon Pharmaceuticals Inc have outstanding?

Lexicon Pharmaceuticals Inc (LXRX) had 366M shares outstanding as of fiscal year 2025.

What is Lexicon Pharmaceuticals Inc's current ratio?

Lexicon Pharmaceuticals Inc (LXRX) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.

What is Lexicon Pharmaceuticals Inc's debt-to-equity ratio?

Lexicon Pharmaceuticals Inc (LXRX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexicon Pharmaceuticals Inc's return on assets (ROA)?

Lexicon Pharmaceuticals Inc (LXRX) had a return on assets of -27.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lexicon Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Lexicon Pharmaceuticals Inc (LXRX) had $34.3M in cash against an annual operating cash burn of $67.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lexicon Pharmaceuticals Inc's Altman Z-Score?

Lexicon Pharmaceuticals Inc (LXRX) has an Altman Z-Score of -7.43, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lexicon Pharmaceuticals Inc's Piotroski F-Score?

Lexicon Pharmaceuticals Inc (LXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexicon Pharmaceuticals Inc's earnings high quality?

Lexicon Pharmaceuticals Inc (LXRX) has an earnings quality ratio of 1.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Lexicon Pharmaceuticals Inc?

Lexicon Pharmaceuticals Inc (LXRX) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.